Heart Outcomes Prevention Evaluation (HOPE-3)
The Heart Outcomes Prevention Evaluation (HOPE-3) SOLARIS Study of Lipid Modification and Blood Pressure Reduction in People at Average Risk trial will evaluate the benefits of combined cholesterol and blood pressure lowering therapies in reducing cardiovascular risk in a wide group of people without vascular disease.
The HOPE-3 study is working with 10,000 middle aged people with no history of cardiovascular disease but have an average level of risk of experiencing disease in their lifetime. Led by The Population Health Research Institute at McMaster University, HOPE-3 will find out if lowering cholesterol and blood pressure will protect someone against future cardiovascular events like heart attacks or strokes.
The results of five years of patient follow-up with identify safe and effective strategies to reduce one's risk of cardiovascular disease for people with average risk, but who could potentially become more susceptible as they age. Helping people to avoid reaching a "high" level of risk can potentially be an effective way of preventing deaths from cardiovascular diseases around the world.
HOPE-3 is expected to identify safe and effective cardiovascular prevention strategies which could substantially reduce the risk of cardiovascular disease (CVD) in a large proportion of middle aged people who are at average risk for vascular events.
HOPE-3 is a large, simple, multicentre, randomised, placebo-controlled trial evaluating the effects of lipid modification and blood pressure lowering with rosuvastatin and a combination of candesartan/hydrochlorothiazide and their combination.
Led by The Population Health Research Institute at McMaster University, a total of 10,000 participants will be recruited in approximately 10 countries and followed for the occurrence of major vascular events over an average of five years.
Simple eligibility criteria will be used based on the absence of pre-existent atherothrombotic vascular disease and age, as the major determinant of risk, in addition to one additional CV risk factor and a clinician’s assessment as to whether an individual does or does not have a clear indication or a contraindication for the therapies being evaluated.